Search | Clinical Trials Finder

Conditions: Total Knee Arthroplasty (TKA)
Interventions: Home Strengthening Exercises, Standard Physical Therapy, Preoperative Assessments; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Gainesville, Florida

Conditions: Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Interventions: Exercise Training; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neuropathic Pain
Interventions: BIIB074; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Charcot-Marie-Tooth Disease, Charcot-Marie-Tooth, Charcot-Marie-Tooth Disease, Type IA, Charcot-Marie-Tooth Disease Type 2A, Charcot-Marie-Tooth Disease Type 2, Charcot-Marie-Tooth Disease, Type 2C, Charcot-Marie-Tooth Disease Type 2A2B, Charcot-Marie-Tooth Disease Type 2B2, Charcot-Marie-Tooth Disease Type 2A1, Charcot-Marie-Tooth Disease Type 4B1, Charcot-Marie-Tooth Disease, Type IB, Charcot-Marie-Tooth Disease Type 2B1, Charcot-Marie-Tooth Disease Type 2U (Diagnosis), Charcot-Marie-Tooth Disease Type 4A, Charcot-Marie-Tooth Disease, Type 4A, Axonal Form, Charcot-Marie-Tooth Disease Type 2A2A, Charcot-Marie-Tooth Disease Type 2S (Disorder), Charcot-Marie-Tooth Disease and Deafness, Charcot-Marie-Tooth Disease Type 4B2, Charcot-Marie-Tooth Disease Type 4H, Charcot-Marie-Tooth Disease Type 1F, Charcot-Marie-Tooth Disease Type 4C, Charcot-Marie-Tooth Disease Type 4E, Charcot-Marie-Tooth Disease Type 1D, Charcot-Marie-Tooth Disease Type 2Q (Diagnosis), Charcot-Marie-Tooth Disease Type 2A2, Charcot-Marie-Tooth Disease Type 2N (Diagnosis), Charcot-Marie-Tooth Disease Type 2B5, Charcot-Marie-Tooth Disease Type 2D, Charcot-Marie-Tooth Disease Type 4D, Charcot-Marie-Tooth Disease Type 2K, Charcot-Marie-Tooth Disease Type 2L (Diagnosis), Charcot-Marie-Tooth Disease Type 2T, Charcot-Marie-Tooth Disease Type 2I, Charcot-Marie-Tooth Disease Type 2J, Charcot-Marie-Tooth Disease Type 2E, Charcot-Marie-Tooth Disease Type 2G, Charcot-Marie-Tooth Disease Type 1C, Charcot-Marie-Tooth Disease Type 2R, Charcot-Marie-Tooth Disease Type 2O (Diagnosis), Charcot-Marie-Tooth Disease Type 2M, Charcot-Marie-Tooth Disease Type 2P, Charcot-Marie-Tooth Disease Type 2Y, Charcot-Marie-Tooth Disease Type 4F (Diagnosis), Charcot-Marie-Tooth Disease Type 4B3, Charcot-Marie-Tooth Disease Type 2H, HNPP, X-Linked Charcot-Marie-Tooth Disease, Charcot Marie Tooth Disease (CMT)
Interventions: Not listed
Lead sponsor: Hereditary Neuropathy Foundation; Government
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions: KYV-101, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: David Porter; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Resistance Exercise, Endurance Exercise, Stretching/Range-of-Motion; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Charlestown, Massachusetts + 1 more

Conditions: Sciatica
Interventions: Radioactive dye, PET/MRI, Blood draw; Drug · Radiation · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia
Interventions: No Intervention; Other
Lead sponsor: Children's National Research Institute; Other
Eligibility: 5 Years to 21 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Complex Regional Pain Syndrome, Sciatica
Interventions: [18F]-FTC-146; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Sclerosis, Myasthenia Gravis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Sarcopenia
Interventions: Endurance exercise, Resistance exercise, Control/Combined training; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dry Needling Technique, Neck Pain Musculoskeletal, Shoulder Pain, Neck Pain, Dry Needling
Interventions: Dry Needling; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
Interventions: Daratumumab and hyaluronidase-fihj; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Human spinal cord stem cell implantation; Device
Lead sponsor: Neuralstem Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida • Evanston, Illinois • Minneapolis, Minnesota

Conditions: Duchenne Muscular Dystrophy
Interventions: Viltolarsen; Drug
Lead sponsor: NS Pharma, Inc.; Industry
Eligibility: 8 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Long Covid, Post-treatment Lyme Disease Syndrome, Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: Lumbrokinase; Dietary Supplement
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Guillain-Barre Syndrome
Interventions: Peripheral nerve ultrasound, Measurement of strength; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Fasudil (WP-0512); Drug
Lead sponsor: Woolsey Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Aurora, Colorado • Denver, Colorado + 6 more

Conditions: Carpal Tunnel Syndrome
Interventions: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Prostatic Neoplasm
Interventions: EZN-4176; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: CyMedica e-vive NMES; Device
Lead sponsor: CyMedica Orthopedics, Inc; Industry
Eligibility: 21 Years to 85 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Blepharoptosis, Lagophthalmos
Interventions: Neuromuscular electrical stimulation, Sham neuromuscular electrical stimulation; Device
Lead sponsor: Brooks Rehabilitation; Other
Eligibility: 19 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Peripheral Neuropathy, Type 1 Diabetes
Interventions: Salsalate; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Total Knee Arthroplasty Biomechanics

Exercise Training in Transthyretin Cardiac Amyloidosis

Absorption, Metabolism, and Excretion Study of BIIB074

Natural History Study for Charcot Marie Tooth Disease

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)

PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Effects of Resistance and Endurance Training on Synthesis of Individual Muscle Proteins in Young and Older Adults

How Dry Needling at the Neck Affects Shoulder Movement, Strength, Pain, and Shoulder Circulation

Daratumumab for Polyneuropathy Associated With MGUS

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Multicenter ALS Imaging Study

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

Evaluation of a Home-based NMES Therapy for Knee Osteoarthritis Pain

NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy